Loading market dashboard
Cencora, Inc.
CORHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
COR bets on MSOs, specialty logistics and AI tools to deepen ties beyond distribution???even as GLP-1 mix and pricing swings cloud results.
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
The mean of analysts' price targets for Cencora (COR) points to a 33.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. ("Cencora" or the "Company") (NYSE: COR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today announced an agreement with Kite, a Gilead Company, to support the distribution of Kite's U.S. Food and Drug Administration (FDA)-approved CAR T-cell therapies, Yescarta® (axicabtagene ciloleucel) and Tecartus® (brexucabtagene autoleucel). The collaboration is designed to support efficient access to the cell therapies at the increasing number of authorized treatment centers in the U.S., including health systems and community oncology practices.
NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. ("Cencora" or the "Company") (NYSE: COR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
CAH and COR are betting big on specialty pharma, but Cardinal Health???s stronger growth, raised outlook, and broader expansion may set it apart.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 29, 2026. Ms. Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financial Officer as previously announced. Mr. Cleary will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Ms. Boratto is an experienced pub.
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
On May 22, 2026, Cencora Inc (COR) shares rose by 3.6% to a current price of $274.91. The stock has experienced a 52-week range between $244.82 and $377.54, ref
U.S. drug distributor Cencora on Thursday raised the lower end of its fiscal 2026 earnings forecast citing recent share repurchases, and also approved a new $2 billion stock buyback plan.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today updated its fiscal year 2026 financial guidance as a result of recent opportunistic share repurchases. Cencora now expects adjusted diluted earnings per share to be in the range of $17.70 to $17.90, up from the previous range of $17.65 to $17.90. The opportunistic share repurchases completed in May align with the Company's previously disclosed expectation that it will repurchase $1.0 billion in shares of common stock by the end.
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. ("Cencora" or the "Company") (NYSE: COR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
LOS ANGELES, May 18, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cencora, Inc. (“Cencora” or “the Company”) (NYSE: COR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cencora, Inc. (NYSE: COR) resulting from allegations that Cencora may have issued materially misleading business information to the investing public. So What: If you purchased Cencora securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rose.
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. ("Cencora" or the "Company") (NYSE: COR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Cencora, Inc. (COR) Presents at BofA Securities 2026 China Conference Transcript
Cencora, Inc. (COR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON CENCORA, INC. (COR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happened?On May 6, 2026, Cenco.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR) investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CENCORA, INC. (COR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith.
Cencora NYSE: COR reported higher fiscal second-quarter adjusted earnings and operating income, while management raised its full-year adjusted EPS outlook and said it would resume opportunistic share repurchases. The pharmaceutical distribution and healthcare services company also lowered its full-year revenue growth expectations, citing faster-than-anticipated brand conversions at a large mail-order pharmacy customer and slower expected growth in GLP-1 products.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CENCORA, INC. (COR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 6, 2026, Cencora released its second quarter 2026 financial results, inclu.
Cencora reported Q2 results with 3.8% revenue growth and a 129% EPS increase, but shares fell sharply, apparently due to a revenue miss. Despite a forward P/E of ~14 and manageable debt, COR faces thin margins, client concentration risks, and headwinds from biosimilars and drug price reductions. Management remains confident, targeting $3B in free cash flow and $1B in share repurchases for 2026, with ongoing M&A to expand specialty services.
Cencora, Inc. (COR) Q2 2026 Earnings Call Transcript
Shares of Cencora Inc. (NASDAQ:COR) are trading lower on Wednesday as the company reported its fiscal 2026 second-quarter results and lowered its annual guidance.
Cencora shares sink after Q2 earnings and revenues miss estimates, even as the company raises its fiscal 2026 EPS outlook.
Cencora (COR) came out with quarterly earnings of $4.75 per share, missing the Zacks Consensus Estimate of $4.8 per share. This compares to earnings of $4.42 per share a year ago.
Cencora reported second-quarter results below Wall Street estimates on Wednesday but raised its annual profit forecast, betting on a steady demand for specialty medicines.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 second quarter ended March 31, 2026, revenue increased 3.8 percent year-over-year to $78.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $8.40 for the second quarter of fiscal 2026 compared to $3.68 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,.
COR heads into Q2 earnings with expected steady specialty-driven growth, but customer losses and pricing pressures could temper results.
Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Cencora (COR). But which of these two stocks presents investors with the better value opportunity right now?
Beyond analysts' top-and-bottom-line estimates for Cencora (COR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cencora (COR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CareDx (CDNA) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.09 per share a year ago.
William Blair launched coverage of Cardinal Health (NYSE:CAH | CAH Price Prediction) with an Outperform rating today, framing the pharma distributor as a durable franchise with specialty-led upside.
As demand for technology-forward patient services accelerates, combined organization positions CareMetx to deliver greater innovation for biopharma clients. As demand for technology-forward patient services accelerates, combined organization positions CareMetx to deliver greater innovation for biopharma clients.
Somehow, members of Congress have turned relatively modest salaries into impressive investment portfolios while the rest of us grind it out in the market.
Assetmark Inc. lifted its stake in shares of Cencora, Inc. (NYSE: COR) by 57.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 67,281 shares of the company's stock after buying an additional 24,431 shares during the quarter. Assetmark Inc.'s holdings in
Massachusetts Financial Services Co. MA lowered its holdings in Cencora, Inc. (NYSE: COR) by 13.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 568,119 shares of the company's stock after selling 89,591 shares during the period. Massachusetts Financial Services Co. MA
Cencora (COR) gets its prior buy rating from 2025 reaffirmed, driven by several strong fundamentals, despite a recent price retreat. The healthcare distributor has a global brand footprint, a key role in serving specific clinical needs, and profitability, despite thin margins. The dividend case is compelling, with proven 10 year growth across many market cycles, and a low payout ratio.
KindlyMD (NASDAQ: NAKA - Get Free Report) and Cencora (NYSE: COR - Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation. Profitability This table compares KindlyMD and Cencora's net margins, return
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 6, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Fin.
Allspring Global Investments Holdings LLC reduced its position in Cencora, Inc. (NYSE: COR) by 9.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 383,068 shares of the company's stock after selling 40,638 shares during the quarter. Allspring Global Investments Holdings LLC owned
Cencora is acquiring EyeSouth's retina business for $1.1 billion, expanding its RCA platform to strengthen foothold in the fast-growing eye care market.
Drug distributor Cencora said on Monday it would buy the retina business of eye care network EyeSouth Partners for $1.1 billion, expanding its eye care unit.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the signing of a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. Upon completion of the transaction, the affiliated retina physicians of EyeSouth Partners will join Cencora's Retina Consultants of America (“RCA”), a leading management services organization (MSO). “Driven by a commitment to empower ophthalmologists, EyeSouth Partners has built a strong regional network of physicians.
Cencora's strong U.S. growth, MSO strategy, and raised outlook support long-term potential, but competition and customer losses remain key risks.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora has engaged an executive search firm to identify and evaluate potential successors from internal and external candidates. Mr. Cleary will assist in the search process and will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Mr. Cleary, 62, has served as Cen.
California Public Employees Retirement System lowered its stake in Cencora, Inc. (NYSE: COR) by 13.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 588,788 shares of the company's stock after selling 93,334 shares during the quarter. California Public Employees Retirement
Chilton Investment Co. Inc. acquired a new stake in shares of Cencora, Inc. (NYSE: COR) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,468 shares of the company's stock, valued at approximately $459,000. Other hedge funds and other
Alliancebernstein L.P. lowered its position in Cencora, Inc. (NYSE: COR) by 21.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 889,802 shares of the company's stock after selling 244,496 shares during the period. Alliancebernstein L.P. owned 0.46% of Cencora worth
Glenmede Investment Management LP reduced its stake in Cencora, Inc. (NYSE: COR) by 2.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 169,665 shares of the company's stock after selling 4,232 shares during the quarter. Glenmede Investment Management
CreativeOne Wealth LLC reduced its stake in Cencora, Inc. (NYSE: COR) by 51.1% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,980 shares of the company's stock after selling 3,119 shares during the quarter. CreativeOne Wealth LLC's holdings in Cencora were worth
Cencora, Inc. (COR) Presents at Leerink Global Healthcare Conference 2026 Transcript
Cencora, Inc. (COR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
